Efficacy and Safety of Tribendimidine Against Clonorchis sinensis
Auteur
Qian, Men-Bao. National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, WHO Collaborative Center for Malaria, Schistosomiasis and Filariasis, Key Laboratory of Parasite and Vector Biology, Ministry of Health, Shanghai, People's Republic of China
Yap, Peiling. Department of Epidemiology and Public Health
Yang, Yi-Chao. Guangxi Center for Disease Control and Prevention, Nanning
Liang, Hai. Binyang Center for Disease Control and Prevention, Binyang, People's Republic of China
Jiang, Zhi-Hua. Guangxi Center for Disease Control and Prevention, Nanning
Li, Wei. Binyang Center for Disease Control and Prevention, Binyang, People's Republic of China
Tan, Yu-Guang. Guangxi Center for Disease Control and Prevention, Nanning
Zhou, Hui. Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute
Utzinger, Jürg. Department of Epidemiology and Public Health
Zhou, Xiao-Nong. National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, WHO Collaborative Center for Malaria, Schistosomiasis and Filariasis, Key Laboratory of Parasite and Vector Biology, Ministry of Health, Shanghai, People's Republic of China
Keiser, Jennifer. Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute
Type de document
Postprint
Langue
Anglais
Publié dans
Clinical Infectious Diseases, 2013, vol. 56, no. 7, p. e76-e82. Oxford University Press
In this randomized open-label trial, tribendimidine was shown to have an efficacy comparable to praziquantel for the treatment of Clonorchis sinensis infection. Patients treated with praziquantel experienced significantly more adverse events than tribendimidine recipients